Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.
Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. Schinke C, et al. Among authors: moorhead m. Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18. Haematologica. 2017. PMID: 28522572 Free PMC article. No abstract available.
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N. Perrot A, et al. Among authors: moorhead m. Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24. Blood. 2018. PMID: 30249784 Free PMC article. Clinical Trial.
Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, Murata R, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S. Takamatsu H, et al. Among authors: moorhead m. Ann Oncol. 2017 Oct 1;28(10):2503-2510. doi: 10.1093/annonc/mdx340. Ann Oncol. 2017. PMID: 28945825 Free PMC article.
A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.
Takamatsu H, Wee RK, Zaimoku Y, Murata R, Zheng J, Moorhead M, Carlton VEH, Kong KA, Takezako N, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S. Takamatsu H, et al. Among authors: moorhead m. Br J Haematol. 2018 Nov;183(4):664-668. doi: 10.1111/bjh.15002. Epub 2017 Dec 22. Br J Haematol. 2018. PMID: 29270982 Free article. Clinical Trial. No abstract available.
Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buño I, Zheng J, Moorhead M, Klinger M, Zhang B, Waqar A, Zehnder JL, Miklos DB. Logan AC, et al. Among authors: moorhead m. Biol Blood Marrow Transplant. 2014 Sep;20(9):1307-13. doi: 10.1016/j.bbmt.2014.04.018. Epub 2014 Apr 24. Biol Blood Marrow Transplant. 2014. PMID: 24769317 Free PMC article.
Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.
Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Zehnder JL, Miklos DB. Logan AC, et al. Among authors: moorhead m. Leukemia. 2013 Aug;27(8):1659-65. doi: 10.1038/leu.2013.52. Epub 2013 Feb 19. Leukemia. 2013. PMID: 23419792 Free PMC article.
Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA. Khodadoust MS, et al. Among authors: moorhead m. Nature. 2017 Mar 30;543(7647):723-727. doi: 10.1038/nature21433. Epub 2017 Mar 22. Nature. 2017. PMID: 28329770 Free PMC article.
Corrigendum to "Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation": [Annals of Oncology 28 (2017):2503-2510].
Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, Murata R, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S. Takamatsu H, et al. Among authors: moorhead m. Ann Oncol. 2023 Mar;34(3):322. doi: 10.1016/j.annonc.2022.08.004. Epub 2022 Sep 6. Ann Oncol. 2023. PMID: 36075840 Free article. No abstract available.
39 results